Class of 2013 Abstract / Specific Aims: To determine if melanoma cells are more vulnerable to Amodiaquine (AQ) or Lumefantrine (LF)-based artemisinin combination therapy compared to artemisinin monotherapy. Methods: Tested anti-malarials in vitro for anti-melanoma activity, which contained 100,000 of the A375 human metastatic melanoma cells that were repeatedly treated independently three times. Main Results: Dihydroartemisinin (DHA) monotherapy induced significant cell death in melanoma cells. However, artemisinin combination therapy (ACT) did not enhance DHA-induced cell death. AQ protected against DHA-induced cell death causing morphological changes detected by electron microscopy. As for LF, it did not affect DHA-induced cell death. Conclusion: The results demonstrated that ACT does not display enhanced anti-melanoma activity compared to artemisinin monotherapy. It suggests that AQ may have anti-oxidant properties, but would need to be explored further in the context of anti-oxidant cyto-protection.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第22883号 / 医博第4677号 / 新制||医||1048(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 平井 豊博, 教授 川上 浩司, 教授 椛島 健治 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM